STOCK TITAN
  1. Home
  2. News
  3. ABBV

ABBVIE INC. - ABBV STOCK NEWS

Welcome to our dedicated page for ABBVIE news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on ABBVIE stock.

AbbVie Inc. (NYSE: ABBV), headquartered in North Chicago, Illinois, is a leading pharmaceutical company ranked 6th on the list of largest biomedical companies by revenue. Known for their commitment to delivering innovative medicines, AbbVie focuses on several key therapeutic areas including immunology, oncology, neuroscience, and eye care. Their portfolio also includes products and services in aesthetics through Allergan Aesthetics, a company they acquired in 2020.

AbbVie’s flagship product, Humira (adalimumab), generated $21 billion in revenue in 2022, accounting for 37% of the company's total revenues. Humira is approved for the treatment of various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. Beyond Humira, AbbVie has developed other notable immunology drugs, including Skyrizi and Rinvoq, which have shown strong market performance.

In the oncology sector, AbbVie markets Imbruvica and Venclexta, which are critical in treating hematological malignancies. The acquisition of Allergan also brought in new products in aesthetics, including Botox, which is not only a cosmetic treatment but also used therapeutically for various conditions.

AbbVie's research and development efforts are robust, with numerous clinical trials ongoing across its therapeutic areas. Recent achievements include positive topline results from the LEVEL UP study, which demonstrated the efficacy of Rinvoq in treating atopic dermatitis. Financially, AbbVie continues to perform well, reporting first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.

Strategic partnerships are also a cornerstone of AbbVie’s growth strategy. Recent collaborations include an agreement with Gilgamesh Pharmaceuticals to develop neuroplastogens for psychiatric disorders and a partnership with Landos Biopharma to enhance their immunology portfolio.

AbbVie remains focused on its mission to address serious health issues and improve patient outcomes globally, leveraging its comprehensive pipeline and innovative solutions in biomedical research.

News

AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline

Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire Cerevel Therapeutics (NASDAQ: CERE) for a total equity value of approximately $8.7 billion. The acquisition adds a robust neuroscience pipeline to AbbVie's portfolio, focusing on psychiatric and neurological disorders. The transaction is expected to close in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.09%
Tags
acquisition
-
News

AbbVie and BigHat Biosciences Announce Research Collaboration to Leverage Artificial Intelligence and Machine Learning to Discover Next-Generation Therapeutic Antibodies

Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) and BigHat Biosciences collaborate to develop next-generation therapeutic antibodies in oncology and neuroscience. BigHat will receive $30 million upfront payment with potential for further milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

Rhea-AI Summary
AbbVie Inc. (NYSE: ABBV) is set to acquire ImmunoGen, Inc. (NASDAQ: IMGN) for $10.1 billion, accelerating its entry into the commercial market for ovarian cancer with the first-in-class antibody-drug conjugate (ADC) ELAHERE®. The transaction, valued at $31.26 per share, aims to diversify AbbVie's oncology pipeline across solid tumors and hematologic malignancies, with potential transformative impact on long-term revenue growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
acquisition
News

AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)

Rhea-AI Summary
AbbVie (NYSE: ABBV) announced topline results from the Phase 2 LUMINOSITY trial for Teliso-V, an investigational first-in-class, c-Met protein directed antibody-drug conjugate (ADC) being studied in patients with previously treated non-small cell lung cancer (NSCLC) with c-Met overexpression. The trial demonstrated a compelling overall response rate of 35 percent and 23 percent across c-Met High and c-Met Intermediate patients respectively, with other meaningful clinical outcomes. Teliso-V has been granted several designations worldwide, including Breakthrough Therapy Designation (BTD) by the U.S. FDA and other health authorities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
clinical trial
-
News

AbbVie Announces U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Rhea-AI Summary
AbbVie (ABBV) announces updates from the Phase 1/2 EPCORE™ NHL-1 clinical trial for epcoritamab, an investigational T-cell engaging bispecific antibody for relapsed or refractory (R/R) follicular lymphoma (FL). The FDA has granted Breakthrough Therapy Designation (BTD) and the EMA has validated a Type II application for epcoritamab for the same indication. If approved, R/R FL would become the second conditionally approved indication for epcoritamab in the European Union.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
none
-
News

Fifth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day Makes History as the Biggest Day Ever

Rhea-AI Summary
Allergan Aesthetics (NYSE: ABBV) achieved record-breaking numbers during the fifth annual BOTOX® Cosmetic Day. November saw the highest number of BOTOX® Cosmetic treatments and gift card sales in history, with over 1.3 million website visitors. Additionally, more than 275,000 Allē members registered for the BOTOX® Cosmetic Day sweepstakes, and the company partnered with Snapchat to create an educational AR Lens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.01%
Tags
none
News

Results Published in The Lancet Show UBRELVY® (ubrogepant) Reduces the Headache Phase of a Migraine Attack When Dosed During the Prodrome of Migraine

Rhea-AI Summary
AbbVie (NYSE: ABBV) announces detailed results published in The Lancet evaluating the efficacy, safety, and tolerability of UBRELVY® (ubrogepant) 100 mg for the acute treatment of migraine during the prodrome phase. The Phase 3 study, PRODROME, showed that UBRELVY significantly reduced the likelihood of developing moderate or severe headache and reduced functional disability compared to placebo within 24 hours post-dose. This is a significant advancement in migraine treatment, providing an opportunity to avoid or attenuate the severity of the headache phase of a migraine attack.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
none
-
News

Natrelle® Unveils New "For Every BODY" Campaign

Rhea-AI Summary
Allergan Aesthetics (NYSE: ABBV) launches 'For Every BODY' campaign to showcase diverse stories and promote its Natrelle® breast implant portfolio. The campaign aims to highlight the importance of personal choice in breast surgery and features real women in various activities and fashion, emphasizing a customized look for every body.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
News

BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Like Never Before

Rhea-AI Summary
Allergan Aesthetics, an AbbVie company, is celebrating the fifth annual BOTOX® Cosmetic Day on November 15. New and loyal members of Allē, the Allergan Aesthetics loyalty program, can enjoy exclusive offers throughout the month of November. These offers include a BOGO free gift card, double points on BOTOX® Cosmetic treatments, and a chance to win $25,000. BOTOX® Cosmetic is also partnering with Snapchat to create an interactive AR Lens.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
none
News

AbbVie Reports Third-Quarter 2023 Financial Results

Rhea-AI Summary
AbbVie reports third-quarter financial results, with diluted EPS of $1.00 on a GAAP basis and $2.95 on an adjusted basis. Net revenues decrease by 6.0% on a reported basis. Immunology portfolio revenues decrease by 11.3%, while neuroscience portfolio revenues increase by 22.1%. AbbVie raises its 2023 adjusted diluted EPS guidance range and announces a dividend increase for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.32%
Tags
earnings

FAQ

What is the current stock price of ABBVIE (ABBV)?

The current stock price of ABBVIE (ABBV) is $166.57 as of November 19, 2024.

What is the market cap of ABBVIE (ABBV)?

The market cap of ABBVIE (ABBV) is approximately 294.4B.

What is AbbVie's primary product?

AbbVie's primary product is Humira (adalimumab), which generated $21 billion in revenue in 2022.

What are the key therapeutic areas AbbVie focuses on?

AbbVie focuses on immunology, oncology, neuroscience, and eye care.

What significant achievement did AbbVie report in their research efforts?

AbbVie reported positive results from the LEVEL UP study, demonstrating the efficacy of Rinvoq in treating atopic dermatitis.

Who are AbbVie's notable partners?

AbbVie has strategic partnerships with companies like Gilgamesh Pharmaceuticals and Landos Biopharma.

What are some of AbbVie's key oncology products?

Key oncology products include Imbruvica and Venclexta.

How did AbbVie perform financially in the first quarter of 2024?

AbbVie reported first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.

What products did AbbVie acquire through Allergan?

Through Allergan, AbbVie acquired products in aesthetics, including Botox.

What is AbbVie's mission?

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues and improve patients' lives globally.

What percentage of revenue did Humira contribute in 2022?

Humira contributed 37% of AbbVie's total revenues in 2022.

Where is AbbVie headquartered?

AbbVie is headquartered in North Chicago, Illinois.

Stock ABBV logo
ABBVIE INC.

NYSE:ABBV

ABBV Rankings

#28 Ranked by Market Cap
#768 Ranked by Dividends

ABBV Stock Data

294.35B
1.77B
0.1%
73.43%
1.03%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
NORTH CHICAGO